Emilia Javorsky
speaker
1,653 appearances
2 recordings
1 series
first heard Mar 2026
last heard 20 Mar
Emilia Javorsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Mar 2026 with 2.
Appearances
Notably, Insilico developed AI tools to target specific bottlenecks at each phase of drug development, from target identification through optimization of clinical trial design.
not only at the discovery phase.
Leveraging AI as a tool to manage complexity and reduce friction throughout the drug development process has emerged as more promising than the narrow focus on molecular discovery alone.
While encouraging, this success is still preliminary, as true success in drug development is defined by FDA approval, insurance coverage, and physician confidence in favorable benefit-to-risk ratios for patients.
Thirteen years into the AI drug discovery movement, we still lack a single FDA-approved drug that cleared the full bar of regulatory approval, reimbursement, and clinical adoption.
The failure point is not intelligence, but the complexity of human biology, the limitations of preclinical models, the friction of drug development, and the challenges of clinical translation.
Market Failures for Life-Saving Medicines
The story of AI-discovered antibiotics deserves special attention because it represents a controlled experiment.
The science was strong enough that there should have been a bidding war to develop the drug.
Yet it faced significant market headwinds.
In 2020, researchers published bespoke AI tools that successfully identified novel antibiotic candidates.
The result was an exciting new antibiotic candidate, the scientist named Halison, an homage to the original AI to go mainstream.
Hal, 9000, from 2001, A Space Odyssey.
Unlike how the AI worked, the chemistry worked, the mouse studies worked.
Further, compared to most drugs, antibiotics that work in mice have a high predictive value to work in humans.
The clinical need is desperate, with antibiotic resistance killing an estimated 1.27 million people globally each year.
But five years later, where are these antibiotics?
The problem wasn't with the science.
It was with the market.
New antibiotics are inherently unprofitable, as they must be used sparingly to avoid promoting resistance, limiting revenue potential.
Showing 821–840 of 1,653 · page 42 of 83
← Previous
Next →